💨 Abstract
Novo Nordisk and Valo Health have expanded their 2023 agreement to develop new treatments for cardiometabolic diseases using AI. The partnership aims to develop up to 20 drugs for obesity, type 2 diabetes, and cardiovascular diseases. The deal could potentially yield Valo near-term payments of up to $190 million and milestone payments of $4.6
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
Legal pedigree not just entrenched in SC. 1 in 3 HC judges related to judges, ex-judges or lawyers
PM Modi to reinforce India's role in strengthening regional cooperation: BIMSTEC Secy Gen
South Korea's Constitutional Court ousts impeached President Yoon
Tariffs place unnecessary strain on US-India ties: Congressman Krishnamoorthi
Trump tariffs provoke world condemnation and fears of a $2,300 iPhone
Melbourne Cricket Ground to beef up security after two charged with guns at football match
Trump's team advising against call with Putin until he agrees to full ceasefire, NBC News reports
Putin envoy Dmitriev sees 'positive dynamic' in U.S.-Russia relations
Argentina Senate rejects Milei nominees to top court
Mexico says 'cool-headed' approach to Trump's tariffs has paid off
Powered by MessengerX.io